Marilyn Hammer BSN, MN, PhD, RN, DC

Dr. Hammer has dedicated her program of research to understanding associations between glycemic status and immune function in patients with cancer, including how these mechanisms impact risks for infection, mortality, and symptom experiences. These investigations that have been federally, regionally, and institutionally funded include understanding individual biosignatures (e.g., demographic, genomic/epigenomic, treatment, environmental, behavioral factors) that place patients at greatest risk for perturbations in glycemic status, termed malglycemia, that can increase the risk for adverse events and worse symptom experiences.